0
Letters |

Funding of Clinical TrialsFunding of Clinical Trials

JAMA. 2006;296(16):1969-1969. doi:10.1001/jama.296.16.1969-a
Text Size: A A A
Published online

AUTHOR INFORMATION

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

FUNDING OF CLINICAL TRIALS

To the Editor: In their study of reported outcomes in major cardiovascular trials, Dr Ridker and Mr Torres1 found that clinical trials funded by for-profit organizations were more likely to report positive findings than those funded by not-for-profit organizations, which were more likely to report results that were negative. One explanation not considered in their discussion is the possibility that the private sector is better able to predict a positive outcome.

The National Institutes of Health funds projects based on the decisions of review committees made up of academic researchers. Such groups may promote studies of public health issues that are neglected by industry because of unprofitable treatments or populations, or test scientifically viable hypotheses without patent-protected sponsors. However, committees of investigators may not safeguard taxpayer dollars in order to maximize a return on investment with the same alacrity as a project officer in a drug or device company who must answer to a board of directors and, ultimately, shareholders. A case in point was the decision by the National Heart, Lung, and Blood Institute to fund the Magnesium in Coronaries (MAGIC) trial for acute myocardial infarction, despite the prior publication of a major trial with 58 000 participants that had negative results.2 The MAGIC trial subsequently had negative results.3

Rather than indict private industry for not funding trials that prove to be negative, decision makers in the public sector should recognize that not every hypothesis merits a major trial. Funding, particularly with public dollars, should be based on picking winners.

Financial Disclosures: None reported.

This letter was shown to Dr Ridker, who declined to reply.—ED.

References
Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005.  JAMA. 2006;2952270-2274
PubMed
 ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction ISIS-4: (Fourth International Study of Infarct Survival) Collaborative Group.  Lancet. 1995;345669-685
PubMed
Magnesium in Coronaries (MAGIC) Trial Investigators.  Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial.  Lancet. 2002;3601189-1196
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005.  JAMA. 2006;2952270-2274
PubMed
 ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction ISIS-4: (Fourth International Study of Infarct Survival) Collaborative Group.  Lancet. 1995;345669-685
PubMed
Magnesium in Coronaries (MAGIC) Trial Investigators.  Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial.  Lancet. 2002;3601189-1196
PubMed
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.